Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α

Shuang CUI,Xiao-Jie PAN,Chao-Liang GE,Yi-Tong GUO,Peng-Fei ZHANG,Ting-Ting YAN,Ji-Yu ZHOU,Qing-Xian HE,Long-Hao CHENG,Guang-Ji WANG,Hai-Ping HAO,Hong WANG

DOI: https://doi.org/10.1016/s1875-5364(21)60039-0

IF: 3.887

2021-06-01

Chinese Journal of Natural Medicines

Abstract:Nonalcoholic fatty liver disease (NAFLD) is regarded as the most common liver disease with no approved therapeutic drug currently. Silymarin, an extract from the seeds of Silybum marianum, has been used for centuries for the treatment of various liver diseases. Although the hepatoprotective effect of silybin against NAFLD is widely accepted, the underlying mechanism and therapeutic target remain unclear. In this study, NAFLD mice caused by methionine-choline deficient (MCD) diet were orally administrated with silybin to explore the possible mechanism and target. To clarify the contribution of peroxisome proliferator-activated receptor α (PPARα), PPARα antagonist GW6471 was co-administrated with silybin to NAFLD mice. Since silybin was proven as a PPARα partial agonist, the combined effect of silybin with PPARα agonist, fenofibrate, was then evaluated in NAFLD mice. Serum and liver samples were collected to analyze the pharmacological efficacy and expression of PPARα and its targets. As expected, silybin significantly protected mice from MCD-induced NAFLD. Furthermore, silybin reduced lipid accumulation via activating PPARα, inducing the expression of liver cytosolic fatty acid-binding protein, carnitine palmitoyltransferase (Cpt)-1a, Cpt-2, medium chain acyl-CoA dehydrogenase and stearoyl-CoA desaturase-1, and suppressing fatty acid synthase and acetyl-CoA carboxylase α. GW6471 abolished the effect of silybin on PPARα signal and hepatoprotective effect against NAFLD. Moreover, as a partial agonist for PPARα, silybin impaired the powerful lipid-lowering effect of fenofibrate when used together. Taken together, silybin protected mice against NAFLD via activating PPARα to diminish lipid accumulation and it is not suggested to simultaneously take silybin and classical PPARα agonists for NAFLD therapy.

pharmacology & pharmacy,integrative & complementary medicine

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the effective treatment plan for non - alcoholic fatty liver disease (NAFLD). Specifically, the study aims to explore whether the natural product silybin can reduce liver lipid accumulation in non - alcoholic fatty liver disease in mice induced by methionine - choline - deficient diet (MCD) by activating peroxisome proliferator - activated receptor α (PPARα). In addition, the study also evaluated the effect of the combined use of silybin and the PPARα agonist fenofibrate to determine whether this combination would have a synergistic or antagonistic effect on the treatment of NAFLD. Through this study, the author hopes to reveal the potential mechanism of silybin in the treatment of NAFLD and provide a theoretical basis for the development of new treatment methods in the future.

Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α

Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease

Supplementation of Silymarin Alone or in Combination with Salvianolic Acids B and Puerarin Regulates Gut Microbiota and Its Metabolism to Improve High-Fat Diet-Induced NAFLD in Mice

Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice.

Silibinin Capsules Improves High Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Hamsters Through Modifying Hepatic De Novo Lipogenesis and Fatty Acid Oxidation

Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity Via Activation of Farnesyl X Receptor.

Silymarin targets the FXR protein through microbial metabolite 7-keto-deoxycholic acid to treat MASLD in obese mice

Silibinin Targeting Heat Shock Protein 90 Represents a Novel Approach to Alleviate Nonalcoholic Fatty Liver Disease by Simultaneously Lowering Hepatic Lipotoxicity and Enhancing Gut Barrier Function

Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice

Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis

Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice

A computer method for cardiac radionuclide kymography.

A biomechanical evaluation of implant, reduction, and prosthesis in the treatment of intertrochanteric hip fractures.

Beneficial effects of silibinin on serum lipids, bile acids, and gut microbiota in methionine-choline-deficient diet-induced mice

Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD

Effect of Silybin Meglumine Tablets on Treatment of Nonalcoholic Steatohepatitis in Rats

Exploring the therapeutic potential of silymarin-based herbal remedy (prebiotic) and probiotic blend in a mouse model of NAFLD: Insights into gut microbiota modulation and liver health

Silybin Meglumine Mitigates CCl4-Induced Liver Fibrosis and Bile Acid Metabolism Alterations

Hepatoprotective Effect and Synergism of Bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic Fatty Liver Disease in Mice

Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.

Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition